Author: Stewart GM1, Wheatley-Guy CM2, Johnson BD1, Shen WK2, Kim CH1
Affiliation:
1Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.
2Department of Cardiovascular Disease, Mayo Clinic, Phoenix, Arizona.
Conference/Journal: J Clin Hypertens (Greenwich).
Date published: 2020 May 13
Other:
Special Notes: doi: 10.1111/jch.13877. [Epub ahead of print] , Word Count: 198
The present study investigated the impact of 12 weeks of pulsed electromagnetic field (PEMF) therapy on peripheral vascular function, blood pressure (BP), and nitric oxide in hypertensive individuals. Thirty hypertensive individuals (SBP > 130 mm Hg and/or MAP > 100 mm Hg) were assigned to either PEMF group (n = 15) or control group (n = 15). During pre-assessment, participants underwent measures of flow-mediated dilation (FMD), BP, and blood draw for nitric oxide (NO). Subsequently, they received PEMF therapy 3x/day for 12 weeks and, at conclusion, returned to the laboratory for post-assessment. Fifteen participants from the PEMF group and 11 participants from the control group successfully completed the study protocol. After therapy, the PEMF group demonstrated significant improvements in FMD and FMDNOR (normalized to hyperemia), but the control group did not (P = .05 and P = .04, respectively). Moreover, SBP, DBP, and MAP were reduced, but the control group did not (P = .04, .04, and .03, respectively). There were no significant alterations in NO in both groups (P > .05). Twelve weeks of PEMF therapy may improve BP and vascular function in hypertensive individuals. Additional studies are needed to identify the mechanisms by which PEMF affects endothelial function.
© 2020 Wiley Periodicals, Inc.
KEYWORDS: anti-hypertensive therapy; hypertension; nitric oxide; vascular function
PMID: 32401418 DOI: 10.1111/jch.13877